Evaluating Haploidentical and Cord Blood Stem Cell Transplantation for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes Using a Novel Sequential Infusion Approach

What this Trial Is About

Researchers are evaluating the clinical effectiveness of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia AML and high-risk myelodysplastic syndromes MDS. The study focuses on comparing different engraftment patternshaploidentical engraftment versus cord blood engraftmentand their effects on outcomes such as immune tolerance, quality of life, early complications, and long-term prognosis. This research aims to provide new evidence for clinical practice by exploring the advantages and effectiveness of this combined transplantation relative to conventional approaches. Treatment involves a novel sequential infusion strategy where haploidentical stem cells are given on Day 0, followed by umbilical cord blood stem cells on Day 6. Patients receive a unique myeloablative conditioning regimen including drugs such as Fludarabine, Cytarabine, Busulfan, ATG, Melphalan, and Cyclophosphamide, with dosing adjusted based on remission status. This approach seeks to balance immune modulation and myeloablation to support long-term cord blood engraftment and reduce complications like graft-versus-host disease. Participants will be closely monitored for outcomes including overall survival measured three years after transplantation. Assessments include immune recovery, relapse rates, graft-versus-host disease incidence, and quality of life evaluations. The study involves follow-up visits and examinations to evaluate hematopoietic recovery, immune tolerance, and long-term prognosis. The total duration includes treatment and extended monitoring to gather comprehensive data on safety and effectiveness.

Haplo-Cord HSCT for AML/MDS